I. Introduction
Platelet-rich fibrin (PRF) is an autologous fibrin matrix rich in leukocyte cytokines and platelets (thrombocytes) and represents the second generation of platelet concentrates
1. The creation of the PRF simplified the preparation of platelet concentrates since using bovine thrombin or anticoagulant is unnecessary. Since no anticoagulant is present, most of the blood sample’s platelets that come into contact with the tube walls activate within a few minutes, causing the coagulation cascades to be released
2. PRF contributes to tissue regeneration through a combination of biological mechanisms. It functions as a bioactive scaffold capable of releasing essential growth factors, such as platelet-derived growth factor (PDGF-a/b and c), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), epidermal growth factor (EGF), connective tissue growth factor (CTGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF), and transforming growth factor β1
3, while also exerting immunomodulatory effects by favoring the polarization of macrophages toward the anti-inflammatory M2 phenotype and attenuating pro-inflammatory cytokines, including TNF-α and IL-6
4,5. In parallel, PRF activates key regenerative signaling pathways that collectively promote cell recruitment, proliferation, and differentiation, as well as angiogenesis and extracellular matrix deposition
6.
Different plasma element concentrations and physicochemical properties can be obtained depending on the preparation technique utilized to create PRF, including leukocyte platelet-rich fibrin (L-PRF)
7, advanced platelet-rich fibrin (A-PRF)
8, injectable platelet-rich fibrin (i-PRF)
9, and concentrated platelet-rich fibrin (C-PRF)
10, each with unique properties and applications. In the preparation of L-PRF, the primary focus of this work, fibrinogen is initially concentrated in the upper section of the tube before being transformed into fibrin through the action of circulating thrombin. Subsequently, a fibrin clot, enriched with serum and platelets, and positioned between the acellular plasma at the top and the red blood cells at the bottom, is extracted from the center of the tube
1.
In the context of oral and maxillofacial surgeries, L-PRF is particularly promising as a regenerative tool for bone and soft tissue procedures
11, such as implant therapy (18.68%), periodontal regeneration (22.42%), and oral surgery (31.14%)
4. L-PRF promotes accelerated healing by creating a fibrin network that mimics the natural fibrin matrix. Clinical outcomes commonly associated with L-PRF include rapid tissue remodeling and a low incidence of infections
12. These results can be attributed to the slow fibrin polymerization that occurs during the PRF processing, which facilitates the incorporation of platelet cytokines and glycan chains into the fibrin mesh. Additionally, during the centrifugation of L-PRF, extensive platelet degranulation indicates a gradual release of cytokines throughout the remodeling of the fibrin matrix
13.
The applicability of L-PRF in oral and maxillofacial surgery is gaining recognition for its unique characteristics that distinguish it from other biomaterials and regenerative techniques. The absence of external additives and the gradual release of growth factors are significant advantages, making it a valuable tool in clinical practice
14. Furthermore, the autologous nature of L-PRF addresses the growing demand for safe, biocompatible treatments that minimize immunological risks while promoting tissue regeneration in a more physiological manner
12. Therefore, this paper aims to add to the literature by describing a series of cases that illustrate the versatility and efficacy of L-PRF in various maxillofacial surgical interventions, providing a more detailed overview of its practical indications and limitations.
IV. Discussion
The application of L-PRF in various oral and maxillofacial surgical procedures has demonstrated promising outcomes, enhancing wound healing, reducing inflammation, and promoting tissue regeneration
12. L-PRF was used in different clinical contexts in this case series, from sinus lifting with bone grafting to socket preservation and third molar extractions. The outcomes observed align with the literature, highlighting L-PRF’s potential to improve soft and hard tissue regeneration due to its autologous nature and ability to gradually release growth factors
11. This series underscores L-PRF’s versatility and effectiveness as an adjunct in surgical procedures aimed at bone preservation, infection control, and postoperative healing.
The development of different types of PRF reflects an evolution in protocols to meet diverse clinical needs. Initially, L-PRF and i-PRF were introduced. L-PRF is a solid PRF membrane that aggregates leukocytes and platelets and can be used to fill and cover various surgical wounds
7. In contrast, i-PRF is a liquid version with a high cell concentration that can be used to irrigate surgical sites, be mixed with bone biomaterials, or even be injected in orofacial procedures
15.
In vitro studies suggest that L-PRF and i-PRF differ in their fibrin ultrastructure: L-PRF presents dense, rough-surfaced fibrin, whereas i-PRF consists of thinner, smoother fibrin, potentially affecting their scaffold functions. However, i-PRF has a lower platelet concentration than solid PRF, which may influence its applications
16.
Following these initial developments, A-PRF was introduced as a modification of L-PRF. A-PRF, also a solid version, is produced with a slightly longer centrifugation time and a significantly lower centrifugation speed
8. A-PRF membranes are smaller than L-PRF membranes and tend to disintegrate more quickly, lasting less than three days
in vitro compared to at least seven days for L-PRF
17. However, A-PRF contains higher levels of growth factors and leukocytes, especially neutrophils, which enhance its regenerative properties
18,19. More recently, A-PRF+ and C-PRF have been developed. A-PRF+ is a refined version that enhances growth factor release for up to ten days, providing a sustained regenerative effect. C-PRF, also a PRF liquid form, is obtained through progressive pipetting and has the highest cellular concentration among platelet aggregates
18. Each PRF type offers unique advantages; for example, while i-PRF is suited for early cell differentiation, A-PRF+ shows more significant potential for mineralization in osteogenic applications
20. Consequently, the choice of PRF protocol and preparation should be tailored to the specific clinical objectives of each procedure.
In the present study, i-PRF was prepared following the original protocol, using centrifugation at 3,300 rpm for 2 minutes
15. More recent investigations have introduced the “low-speed centrifugation concept”, which applies reduced centrifugal forces (approximately 700 rpm for 3 minutes) and has been associated with higher concentrations of platelets, leukocytes, and circulating progenitor cells, thereby promoting a more sustained release of growth factors and cytokines
10,21. Nevertheless, the classical protocol was adopted in the present work to ensure methodological consistency, facilitate comparison with previous studies, and align with the standardized procedures routinely employed in our laboratory.
Due to its 10- to 14-day resorption period, complete biocompatibility, and size adequate to cover most small perforations, L-PRF is recommended as a treatment for Schneiderian membrane perforations. However, for ethical reasons, randomized controlled trials assessing L-PRF specifically for this application are not feasible, as they would require either intentionally created membrane tears or a large sample size to capture the relatively rare cases of accidental perforations
22. Nonetheless, observational studies have shown promising results. Increased angiogenesis was observed in the sinus area in patients treated with L-PRF after maxillary sinus membrane perforations. Additionally, implant survival rates were reported as 100%, with no signs of peri-implant bone loss
23. In line with these findings, our study successfully used L-PRF as a secondary measure to address persistent oroantral communication after initial surgical attempts.
In sinus lift procedures, a systematic review found no significant difference in the percentage of new bone formation when L-PRF was added to a bone substitute compared to when it was not
22. However, Tatullo et al.
24 demonstrated that combining L-PRF with biomaterial reduced healing time to approximately 106 days, promoting optimal bone regeneration and achieving favorable primary stability for endosseous implants. Clinically, the association of PRF with biomaterial is also considered more manageable to handle compared to biomaterial moistened only with saline solution. In addition, one of the benefits of using L-PRF during maxillary sinus lift procedures is its ability to replace collagen membranes. Studies have shown that L-PRF membranes offer similar outcomes to commercially available collagen membranes
25, with additional benefits: they are more cost-effective and derived from the patient’s blood, enhancing biocompatibility
22. Although the case presented here uses L-PRF combined with biomaterial as a membrane to protect the lateral window, reports support L-PRF isolated use in sinus-lifting procedures
26.
According to current research, L-PRF enhances alveolar preservation around dental implants and in extraction sockets
22. When comparing L-PRF-treated sites to control sites with only blood clots, studies have shown significant improvements in alveolar ridge contour, socket bone fill, vertical gain of the buccal cortical plate, and bone density
11. Additionally, L-PRF has been associated with reduced patient discomfort, as indicated by visual analog scale scores
27. In third molar extractions, L-PRF has been shown to decrease the incidence of alveolar osteitis in the first week after mandibular third molar surgery, reducing the risk by 62% compared to untreated sites
22. L-PRF also correlates with less postoperative pain, reduced swelling
28,29, and improved hard tissue healing
30. For post-extraction socket management, we recommend placing an L-PRF plug in the socket to accelerate angiogenesis, facilitate tissue remodeling, promote cell migration, prevent necrosis, and reduce infection risk. Additionally, covering this plug with an additional L-PRF membrane can help protect and close the wound, stimulate the wound margins, act as a barrier against contaminants, and prevent competing tissue ingrowth.
In addition to the uses of L-PRF discussed in the clinical cases presented in this article, such as closing oroantral communications, post-extraction treatment of third molars, sinus lifting, and alveolar preservation, other studies highlight additional applications of L-PRF. For instance, L-PRF combined with iliac crest grafts has significantly improved outcomes in promoting bone regeneration for alveolar cleft reconstruction
22. In partially edentulous patients, L-PRF reduced peri-implant bone resorption following tooth extraction with immediate implant placement
31, enhancing implant stability during the early healing phase and promoting faster osseointegration
32. L-PRF has also effectively filled bone defects in cystic lesions post-enucleation
33. In cases of osteonecrosis of the jaw, L-PRF promoted rapid epithelialization within 4 weeks to 3 months, resulting in complete bone closure in most cases
11.
However, it is essential to highlight that the technique can be sensitive to the operator and their ability to collect the blood and quickly centrifuge the sample. This is because, in the absence of an anticoagulant, blood samples coagulate nearly instantly as they come into contact with the tube walls, and centrifugation only takes a few minutes to concentrate fibrinogen in the tube
34. Quick handling is the only way to obtain a clinically usable L-PRF clot. Consequently, failure will result from an excessively lengthy time needed to gather blood and begin centrifugation; the fibrin will polymerize in the tube, dispersed, producing only a tiny, inconsistent blood clot
1. In that way, the quickness of blood collection and prompt transfer to the centrifuge, typically within a minute, are critical to the L-PRF technique’s success
7. The fibrin architecture of L-PRF is significantly affected by the centrifugation procedures and the properties of the centrifuge itself. A concern arises from vibrations exceeding the recommended levels in some machines on the market. Elevated vibration levels during the centrifugation process can harm the cellular content and disrupt the organization of fibrin
17.
Regarding venipuncture, a peripheral venous catheter can be used for administering fluids, nutrients, medications, and blood products, as well as for collecting blood for laboratory testing, as in the present study. However, its use is not without risk of complications, which may include local or systemic events that compromise patient safety
35. Phlebitis and catheter-associated infections are among the most common complications associated with this procedure. To minimize such risks, it is recommended to select appropriate devices based on the insertion site, to use disposable tourniquets at a safe distance from the puncture site, and to adopt tools that assist in the visualization of blood vessels through imaging devices
36. To reduce the occurrence of these complications and improve the technique, simulation-based education has been increasingly incorporated into the training of healthcare professionals. As applied in this study, simulated skills training using mannequins or anatomical models that mimic the human body allows for repeated practice of the procedure prior to performing it on actual patients, thereby reducing potential risks
37.
The cases presented confirm that PRF can enhance healing, reduce post-operative discomfort, and support bone regeneration in oral and maxillofacial surgery
11,24,27. However, its inclusion should be evaluated case by case, considering patient-specific needs and treatment goals. While PRF is not necessary in all procedures, it is highly recommended in cases requiring accelerated healing, reduced infection risk, or enhanced bone formation, such as complex extractions or bone defect treatments
12,22,30,38. Future studies, particularly large randomized trials, are suggested to standardize PRF protocols and assess long-term outcomes across different patient profiles, especially those with systemic health conditions. The use of PRF is a promising, cost-effective, and biocompatible option to improve outcomes in suitable cases.